Method for synthesizing deoxythymidine

By using Compound A as the starting material, using protection, condensation, ammonialysis and ring formation reaction steps, the problems of complex and high cost of deoxythymidine synthesis in the prior art are solved, and a simplified synthesis route suitable for industrial production is realized. , reduces production costs.

CN118930594APending Publication Date: 2024-11-12NANJING PET TRACER
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310512772.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-09
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the existing deoxythymidine synthesis route, the starting raw materials are expensive, the production cost is high, and the synthesis process is complex, making it difficult to adapt to industrial production needs.

Method used

Using compound A (2-deoxy-D-erythryl-pentanosamine) as the starting material, a new process is achieved through a series of specific chemical reaction steps, including protection, condensation, ammonia dissolution, ring formation and deprotection. Synthetic deoxythymidine route.

Benefits of technology

The synthesis process is simplified, the raw material cost is reduced, and the production of deoxythymidine is more suitable for industrial applications, providing a simple and economical synthesis path.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention belongs to the field of medical intermediates, and particularly relates to a method for synthesizing deoxythymidine. According to the invention, 2-deoxy-D-erythro-furan pentose amine is used as an initial raw material, and a brand new route for synthesizing deoxythymidine is provided. The route has the advantages of simple synthesis process, easily available raw materials and lower cost, and can be applied to industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical intermediates, and specifically relates to a method for synthesizing deoxythymidine. Background Art

[0002] Deoxythymidine is synthesized 18 The synthetic raw material of F-FLT labeling precursor is also the main raw material for synthesizing anti-AIDS drugs Zidovudine and Stavudine. There is no natural product. Its structural formula is as follows:

[0003]

[0004] The main starting materials of the existing synthetic route of the compound are D-ribose (CN1634959A), 2-deoxy-D-ribose (CN104513287B) or 5-methyluridine (CN102863493A, CN102086222A), and these methods have the disadvantages of expensive raw materials, high production cost, and complex synthetic process. The synthetic route disclosed in the present invention has the advantages of simple synthetic process, easy to obtain raw materials, low cost, and can be applied to industrial production. Summary of the invention

[0005] The present invention uses compound A (2-deoxy-D-erythro-pentofuranosamine) as a starting material, provides a new route for synthesizing deoxythymidine, and is achieved through the following technical scheme:

[0006] The synthesis method of deoxythymidine provided by the present invention uses compound A as a starting material, and the structure of compound A is as follows:

[0007] .

[0008] The method comprises the following steps:

[0009] (1) Protecting the vicinal dihydroxyl group of compound A to obtain compound I;

[0010] (2) Compound I and ethyl 2-formylpropionate undergo condensation reaction to obtain compound II;

[0011] (3) Compound II is subjected to an aminolysis reaction to obtain compound III;

[0012] (4) Compound III undergoes a cyclization reaction with COCl2 to obtain compound IV;

[0013] (5) Compound IV is deprotected from the hydroxyl group to obtain deoxythymidine.

[0014] The specific synthetic route of the method is:

[0015]

[0016] Wherein, R is a silyl ether protecting group, or two R groups together form a -C(CH3)2 protecting group.

[0017] Specifically, the silyl ether protecting group is TES or TBDMS.

[0018] In step (1), the vicinal dihydroxyl group of compound A is protected to obtain compound I.

[0019] Furthermore, in step (1), when R is a silyl ether protecting group, the reaction solvent is DMF or dichloromethane, and compound A reacts with a silyl ether protecting group reagent in the presence of a basic catalyst to obtain compound I.

[0020] The silyl ether protecting group reagent is TESCl or TBDMSCl; the molar ratio of the compound A to the silyl ether protecting group reagent is 1:(2-5); preferably, the molar ratio of the compound A to the silyl ether protecting group reagent is 1:(2-3); the reaction temperature is 0-50°C.

[0021] Specifically, the alkaline catalyst is selected from any one of DIEA, DIPEA, TEA and imidazole.

[0022] Furthermore, when two R groups together form a -C(CH3)2 protecting group, the reaction solvent is acetone, and compound I is prepared under the action of an acidic catalyst; the reaction temperature is 0~50°C.

[0023] Specifically, the acidic catalyst is any one of hydrochloric acid, sulfuric acid or p-toluenesulfonic acid.

[0024] In step (2), compound I and ethyl 2-formylpropionate undergo condensation reaction to obtain compound II.

[0025] In the step (2), compound I reacts with ethyl 2-formylpropionate in a methanol solvent at 0-50°C to obtain compound II. Preferably, the reaction temperature is 20-30°C.

[0026] Furthermore, the molar ratio of compound I: ethyl 2-formylpropionate is 1:(1-3); preferably, the molar ratio of compound I: ethyl 2-formylpropionate is 1:(1.0-1.5).

[0027] In step (3), compound II is subjected to an aminolysis reaction to obtain compound III.

[0028] In the step (3), compound II and concentrated aqueous ammonia react in a methanol solution at a reaction temperature of 10-40° C. Preferably, the reaction temperature is 20-30° C.

[0029] Furthermore, the molar ratio of compound II to concentrated aqueous ammonia is 1:(3-6); preferably, the molar ratio of compound II to concentrated aqueous ammonia is 1:5.

[0030] In step (4), compound III undergoes a cyclization reaction with COCl2 to obtain compound IV.

[0031] In the step (4), a basic catalyst NaH or t-BuOK is used, and the reaction solvent is DMF, DME or toluene, and compound IV is prepared at 10-40°C.

[0032] Furthermore, the molar ratio of compound III:COCl2 is 1:(1-3); preferably, the molar ratio of compound III to COCl2 is 1:(1.0-1.5).

[0033] In step (5), the hydroxy protecting group of compound IV is removed to obtain deoxythymidine.

[0034] In the step (5), the reagent for removing the hydroxyl protecting group is selected from any one of acetic acid, trifluoroacetic acid, TMSBr or TBAF.

[0035] Specifically, the synthetic route when using a silyl ether protecting group to protect the vicinal dihydroxyl group is:

[0036]

[0037] Wherein, R1 is TES or TBDMS.

[0038] Specifically, the synthetic route when using -C(CH3)2 to protect the vicinal dihydroxyl group is:

[0039]

[0040] Compared with the prior art, the beneficial effects of the present invention are as follows: the present invention provides a new route for synthesizing deoxythymidine, the synthesis process is simple, the raw materials are easily available, the cost is low, and it can be applied to industrial production. DETAILED DESCRIPTION

[0041] The present invention will be further described below in conjunction with embodiments, but the protection scope of the present invention is not limited thereto.

[0042] Example 1

[0043] (1) Synthesis of Compound Ia

[0044]

[0045] Compound A (1.5 mmol) was dissolved in 5 mL of anhydrous acetone, concentrated sulfuric acid (0.035 mL) was added dropwise, and stirred at room temperature for 6 h. The reaction was terminated. The reaction mixture was neutralized to pH = 7 with 10% sodium hydroxide solution and concentrated to half under reduced pressure. The residue was extracted with dichloromethane, and the organic phase was spin-dried. The solid was crystallized from ethanol to obtain compound Ia (1.4 mmol) with a yield of 93%.

[0046] 1 H NMR (500 MHz, CDCl3): δ 4.80 – 4.71 (m, 1H), 4.29 (q, J = 7.0 Hz, 1H), 4.19 – 4.10 (m, 2H), 4.05 (dd, J = 7.5, 6.1 Hz, 1H), 4.02 – 3.92 (m, 2H), 2.15 (t, J = 7.0 Hz, 2H), 1.44 (s, 3H), 1.39 (s, 3H).

[0047] (2) Synthesis of compound II-a

[0048]

[0049] Ethyl 2-formylpropionate (1.0 mmol) and compound Ia (1.0 mmol) were added to the reaction flask, and 20 mL of methanol solution was added and stirred at room temperature for 24 h. The reaction was stopped and the crude compound II-a was directly used in the next step without treatment.

[0050] (3) Synthesis of compound III-a

[0051]

[0052] Concentrated aqueous ammonia (5.0 mmol) was added dropwise to the solution of the previous reaction at room temperature. The mixture was stirred for 1 h and then heated to reflux for 6 h. After the reaction was completed, the temperature was lowered and filtered to obtain compound III-a (0.81 mmol) with a yield of 81%.

[0053] 1H NMR (500 MHz, CDCl3): δ 8.02 (dd, J = 9.0, 7.1 Hz, 1H), 6.83 (d, J =6.8 Hz, 1H), 6.71 (ddt, J = 9.0, 2.0, 1.0 Hz, 1H), 6.64 (d, J = 6.8 Hz, 1H), 4.86 (qd, J = 7.0, 1.6 Hz, 1H), 4.24 (q, J = 7.0 Hz, 1H), 4.15 (q, J = 7.0 Hz, 1H), 4.00 (dd, J = 6.9, 0.8 Hz, 2H), 2.19 (t, J = 7.0 Hz, 2H), 1.87 (d, J = 1.1Hz, 3H), 1.46 (s, 3H), 1.41 (s, 3H).

[0054] (4) Synthesis of compound IV-a

[0055]

[0056] Compound III-a (0.5 mmol) and NaH were stirred in DMF solution at room temperature for 2.5 h, COCl2 (0.6 mmol) was added, and stirring was continued at room temperature for 16 h. The solvent was removed to obtain compound IV-a (0.48 mmol) with a yield of 96%.

[0057] (5) Synthesis of deoxythymidine

[0058]

[0059] 80% acetic acid solution (20 mL) was added to compound IV-a (0.4 mmol), and the mixture was refluxed for 2 h. The reaction endpoint was monitored by TLC. After the reaction, the reaction solution was concentrated to obtain a crude product, which was recrystallized to obtain deoxythymidine (0.36 mmol) with a yield of 90%.

[0060] Example 2

[0061] (1) Synthesis of compound Ib

[0062]

[0063] Compound A (1 eq) and DIEA (1.5 eq) were dissolved in anhydrous DMF, followed by the addition of chlorotriethylsilane (2.4 eq), and the mixture was heated to 60°C for 4 h. The reaction was monitored by TLC. After the reaction, the solvent was removed and the compound Ib was purified by column with a yield of 88%.

[0064] 1H NMR (500 MHz, CDCl3): δ 4.72 (tt, J = 7.0, 6.0 Hz, 1H), 4.49 (dd, J =7.6, 6.1 Hz, 1H), 4.19 (dd, J = 7.5, 6.0 Hz, 1H), 4.13 (q, J = 7.0 Hz, 1H), 4.02 (q, J = 7.0 Hz, 1H), 3.75 (dd, J = 12.4, 6.9 Hz, 1H), 3.65 (dd, J = 12.5, 7.0Hz, 1H), 2.25 – 2.12 (m, 2H), 0.87 (td, J = 7.9, 6.2 Hz, 17H), 0.73 – 0.53 (m,13H).

[0065] (2) The synthesis process of compound II-b is the same as that of Example 1.

[0066] (3) The synthesis process of compound III-b is the same as that of Example 1.

[0067] (4) The synthesis process of compound IV-b is the same as that of Example 1.

[0068] (5) Synthesis of deoxythymidine

[0069]

[0070] Add TMSBr (6 eq) to a methanol solution of compound IV-b (1 eq), and stir the reaction mixture at room temperature for 10 min. After the reaction is completed, add saturated sodium bicarbonate aqueous solution (1 mL) to quench the reaction solution. Add water (10 mL) and extract the product with ethyl acetate (3 × 10 mL). Wash the organic phase with brine (20 mL) and concentrate to obtain deoxythymidine with a yield of 85%.

[0071] Example 3

[0072] (1) Synthesis of compound Ic

[0073]

[0074] Compound A (1 eq) was dissolved in CH2Cl2, DIPEA (1.5 eq) was added thereto, and then tert-butyldiphenylsilyl chloride (2.5 eq) was added to the system. The mixture was stirred at room temperature for 2 h. After the reaction was completed, CH2Cl2 was evaporated under reduced pressure to obtain a crude product. The crude product was dissolved in ethyl acetate, and then the ethyl acetate was washed three times with water and once with brine. The organic phase was concentrated under reduced pressure to obtain compound Ic with a yield of 80%.

[0075] 1 H NMR (500 MHz, CDCl3): δ 4.72 (tt, J = 7.0, 6.0 Hz, 1H), 4.49 (dd, J =7.6, 6.1 Hz, 1H), 4.19 (dd, J = 7.5, 6.0 Hz, 1H), 4.11 (q, J = 7.0 Hz, 1H), 4.03 (q, J = 6.9 Hz, 1H), 3.77 (dd, J = 12.4, 6.9 Hz, 1H), 3.67 (dd, J = 12.4, 7.0Hz, 1H), 2.26 – 2.13 (m, 2H), 0.87 (d, J = 13.5 Hz, 18H), 0.05 (d, J = 17.9 Hz,12H).

[0076] (2) The synthesis process of compound II-c is the same as that of Example 1.

[0077] (3) The synthesis process of compound III-c is the same as that of Example 1.

[0078] (4) The synthesis process of compound IV-c is the same as that of Example 1.

[0079] (5) Synthesis of deoxythymidine

[0080]

[0081] Compound IV-c (1 eq) was dissolved in anhydrous tetrahydrofuran, and then a tetrahydrofuran solution of TBAF (6 eq) was added dropwise. The mixture was stirred for 24 h under argon protection and monitored by TLC. After the reaction, an NH4Cl aqueous solution was added to the mixture, and the mixture was extracted with ethyl acetate several times. The organic phase was dried over MgSO4 and concentrated under reduced pressure to obtain deoxythymidine with a yield of 82%.

[0082] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principles of the present invention shall be equivalent replacement methods and shall be included in the protection scope of the present invention.

Claims

1. A method for synthesizing deoxythymidine, characterized in that: Deoxythymidine was prepared using compound A as a starting material, and the structure of compound A is as follows: 。 2. The method according to claim 1, characterized in that The method comprises the following steps: (1) Protecting the vicinal dihydroxyl group of compound A to obtain compound I; (2) Compound I and ethyl 2-formylpropionate undergo condensation reaction to obtain compound II; (3) Compound II is subjected to an aminolysis reaction to obtain compound III; (4) Compound III undergoes a cyclization reaction with COCl2 to obtain compound IV; (5) Compound IV is deprotected from the hydroxyl group to obtain deoxythymidine.

3. The method according to claim 2, characterized in that The specific synthetic route of the method is: ; Wherein, R is a silyl ether protecting group, or two R groups together form a -C(CH3)2 protecting group.

4. The method according to claim 3, characterized in that The silyl ether protecting group is TES or TBDMS.

5. The method according to claim 3, characterized in that: In the step (1), when R is a silyl ether protecting group, compound A and an ether protecting group reagent are reacted under the action of a basic catalyst to prepare compound I; the reaction solvent is DMF or dichloromethane, the reaction temperature is 0-50° C., and the molar ratio of compound A to the silyl ether protecting group reagent is 1:(2-5); When two R groups together form a -C(CH3)2 protecting group, the reaction solvent is acetone, and compound I is prepared under the action of an acidic catalyst.

6. The method according to claim 5, characterized in that The alkaline catalyst is selected from any one of DIEA, DIPEA, TEA and imidazole; the acidic catalyst is selected from any one of hydrochloric acid, sulfuric acid or p-toluenesulfonic acid.

7. The method according to claim 3, characterized in that In the step (2), compound I reacts with ethyl 2-formylpropionate in a methanol solvent at 0-50° C. to obtain compound II; the molar ratio of compound I to ethyl 2-formylpropionate is 1:(1-3).

8. The method according to claim 3, characterized in that In the step (3), the molar ratio of compound II to concentrated aqueous ammonia is 1:(3-6), methanol is used as the solvent, and compound III is prepared at 0-40°C.

9. The method according to claim 3, characterized in that: In the step (4), an alkaline catalyst NaH or t-BuOK is used, and the reaction solvent is selected from any one of DMF, DME or toluene, and compound IV is prepared at 0-40°C; the molar ratio of compound III to COCl2 is 1:(1-3).

10. The method according to claim 3, characterized in that In the step (5), the reagent for removing the hydroxyl protecting group is selected from any one of acetic acid, trifluoroacetic acid, TMSBr or TBAF.

Citation Information

Cited By

  • Method for preparing sodium stannate and co-producing barium stannate by utilizing tin-containing wastewater of beta-thymidine production process

    CN120328610A